306 related articles for article (PubMed ID: 30639620)
1. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Davies KD; Lomboy A; Lawrence CA; Yourshaw M; Bocsi GT; Camidge DR; Aisner DL
J Thorac Oncol; 2019 Apr; 14(4):737-741. PubMed ID: 30639620
[TBL] [Abstract][Full Text] [Related]
2. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
5. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
6. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
7. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
8. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
9. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
Sui JSY; Finn SP; Gray SG
Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
[TBL] [Abstract][Full Text] [Related]
10. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
11. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
12. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
Heist RS; Shim HS; Gingipally S; Mino-Kenudson M; Le L; Gainor JF; Zheng Z; Aryee M; Xia J; Jia P; Jin H; Zhao Z; Pao W; Engelman JA; Iafrate AJ
Oncologist; 2016 Apr; 21(4):481-6. PubMed ID: 27022036
[TBL] [Abstract][Full Text] [Related]
13. An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
Teishikata T; Shiraishi K; Shinno Y; Kobayashi Y; Kashima J; Ishiyama T; Yoshida T; Mori T; Yatabe Y
J Thorac Oncol; 2021 Dec; 16(12):2133-2138. PubMed ID: 34419686
[TBL] [Abstract][Full Text] [Related]
14. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
Ding G; Wang J; Ding P; Wen Y; Yang L
Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
[TBL] [Abstract][Full Text] [Related]
15. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Sunami K; Furuta K; Tsuta K; Sasada S; Izumo T; Nakaoku T; Shimada Y; Saito M; Nokihara H; Watanabe S; Ohe Y; Kohno T
J Thorac Oncol; 2016 Feb; 11(2):203-12. PubMed ID: 26845116
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
17. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14
Skipping Mutation].
Editorial Office of Chinese Journal of Lung Cancer
Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):416-428. PubMed ID: 37488079
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With
Hur JY; Ku BM; Shim JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
In Vivo; 2020; 34(3):1399-1406. PubMed ID: 32354937
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
[TBL] [Abstract][Full Text] [Related]
20. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
